Abstract: The present disclosure relates to self-emulsifying pharmaceutical compositions for transmucosal delivery of biologically active peptides and proteins.

Abstract: Extended-release, injectable microsphere formulations comprising ketamine are provided. Methods for making and using the microsphere formulations are also provided.

Abstract: The invention discloses a lenalidomide gastro-retentive sustained-release tablet and a preparation method thereof. The sustained-release tablet comprises 3 wt % to 14 wt % of lenalidomide, 14 wt % to 68 wt % of release enhancer with low bulk density, 23 wt % to 70 wt % of sustained-release material with low bulk density, and the balance of other pharmaceutically acceptable excipients, wherein the bulk density of the release enhancer ranges from 0.24 g/cm3 to 0.52 g/cm3; and the bulk density of the sustained-release material ranges from 0.29 g/cm3 to 0.51 g/cm3. The sustained-release tablet of the invention is in a floating state in a gastric environment, is not directly discharged from a stomach due to gastric emptying, has an effect of gastric retention, and is not easily discharged with substances contained in the stomach, and has a high drug bioavailability and small side effects.

Abstract: Silver and titanium oxide nanoparticles produced with Fomes fomentarius or Fomitopsis pinicola aqueous extracts and methods for treating bacterial infections or cancer using them.

Abstract: The present invention concerns polymer particles made from poly(lactic-co-glycolic acid) (PLGA) polymer, poly(lactic-co-glycolic acid)-polyethylene glycol-poly(lactic-co-glycolic acid) (PLGA-PEG-PLGA) copolymer, or the mixture of same, combined with hyaluronic acid molecules or hyaluronic acid salts, and the method for preparing same. The present invention also concerns injectable pharmaceutical or cosmetic compositions comprising such polymer particles, the method for preparing such compositions, and the use thereof for medical purposes, in particular for the prevention and/or treatment of musculoskeletal diseases, diseases and traumatic conditions of the skin, oral disorders, vaginal mucosa dryness and urinary infections or cystitis, dryness of the eye membrane and eye infections, obesity, and the use of same to combat ageing of the skin and/or for repairing the dermal tissue (mesotherapy).

Abstract: Provided is a core-shell structure having an excellent immediate effect in transdermal absorption of an active ingredient. A core-shell structure comprising a core portion containing an active ingredient, and a shell portion containing a surfactant having an HLB value of 4 to 14, the core portion being solid, and the surfactant containing a saturated hydrocarbon group having 7 to 15 carbon atoms or an unsaturated hydrocarbon group having 7 to 17 carbon atoms.

Abstract: The invention pertains to methods of manufacturing soft chews containing highly heat-labile and moisture-labile active agents. The invention pertains to methods for manufacturing soft chew, comprising a) heating at a non-aqueous liquid carrier to a temperature of at least about 50° C., b) mixing the heated non-aqueous liquid carrier with at least one binding agent to form a uniform solution, c) mixing a solid excipient with the mixture produced in step b) to form a smooth dough, d) cooling the dough to about 30° C., e) mixing an active agent with the cooled dough, and f) forming soft chews from the dough produced in step e). The invention also pertains to soft chews manufactured by the methods of the invention. The soft chews produced according to these methods exhibit surprisingly higher stability of moisture-labile active agents while still providing desirable soft chew properties, such as soft moisture texture, taste, and palatability.

Abstract: Multi-layer microcapsules comprising a core comprising one or more active agents and two or more shells comprised of a wall-forming polymeric material, an opaque substance and a fatty acid salt, which are rupturable upon rubbing or pressing on the skin, are disclosed. The microcapsules are characterized by improved lightness values (L*) and/or compatibility in aqueous solution-containing formulations. Cosmetic or cosmeceutic formulations comprising the microcapsules, which can be, for example, body skin care formulation or facial skin care formulations, are also provided.

Abstract: The present disclosure provides a skin care formulation, which includes silver nanoparticles (AgNPs) and/or silver microparticles (AgMPs), vitamin E, glycerin, hyaluronic acid or a salt thereof, and water. The skin care formulation may be in a form of a serum. The present formulation may be used for treating a skin condition, such as aging, wrinkle, or pigmentation. The present formulation also may be used for moisturizing, rejuvenating, repairing, or improving aesthetic appearance of a skin of a subject in need thereof.

Abstract: Cosmetic compositions, including hair coloring compositions, comprising graphene oxide (GO), reduced graphene oxide (r-GO), or both, and water are provided.

Abstract: A method of making Cu—Ag3PO4 nanoparticles is provided. The method includes forming a mixture of at least one silver salt, at least one phosphate salt, and at least one copper (II) salt. The method further includes dissolving the mixture in water. The method further includes sonicating the mixture. The method further includes precipitating the Cu—Ag3PO4 nanoparticles or “nanoparticles”. The copper is present in the nanoparticles in an amount of 2 to 23 weight percent (wt. %) based on the total weight of the Cu—Ag3PO4. The nanoparticles of the present disclosure find application in treating cervical cancer, and colorectal cancer. The nanoparticles may also be used in photodegrading environmental pollutants.

Abstract: Disclosed in certain embodiments is an immediate release solid oral dosage form comprising a plurality of particles, each particle comprising: (i) a core comprising a first active agent; (ii) a coating comprising a second active agent layered over the core; and (iii) a material that is sensitive to acidic pH layered over the coated core; wherein the dosage form releases at least about 70% of the second active agent within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml 0.1 N HCl at 37° C.

Abstract: The present invention refers to a particulate pharmaceutical or nutraceutical excipient, a process for the preparation of the particulate pharmaceutical or nutraceutical excipient, a pharmaceutical or nutraceutical composition comprising the particulate pharmaceutical or nutraceutical excipient as well as a process for manufacturing a pharmaceutical or nutraceutical composition.

Abstract: The present invention relates to a process for semi-permanent straightening and permanent shaping hair, especially human hair, for improved and milder semi-permanent straightening and permanent shaping. It is found out that when commonly used permanent shaping reducing composition is mixed with another composition comprising predominantly carboxylic acids, the permanent shaping effect of the composition is improved, homogeneous shaping of hair fibers is achieved and natural cosmetic properties of hair is maintained and hair may be semi-permanently straightened before such process.

Abstract: The present invention provides a radiation sensitizer or anti-cancer chemotherapy sensitizer that prevents the decomposition of hydrogen peroxide for a longer period of time, and that maintains its effect. The radiation sensitizer or anti-cancer chemotherapy sensitizer according to the present invention is characterized by using hydrogen peroxide together with a hydrogel containing a crosslinked gelatin gel.

Abstract: The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe3O4, as well as compositions containing HSS.

Abstract: The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe3O4, as well as compositions containing HSS.

Abstract: The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe3O4, as well as compositions containing HSS.

Abstract: The present invention provides a method for preparing a bone protein preparation which contains for example growth factors. The present invention also provides a bone protein preparation obtained by the method and paste, putty, pellet, disc, block, granule, osteogenic device or pharmaceutical composition containing said bone protein preparation.

Abstract: A tissue adhesive membrane and a preparation method thereof are provided. The tissue adhesive membrane includes a supramolecular polymer and an enhancer; the supramolecular polymer is prepared by copolymerization of lipoic acid and a biocompatible stabilizer; and the enhancer includes at least one selected from the group consisting of a cationic compound, a cationic polymer, and a metal particle. The tissue adhesive membrane of the present invention can achieve rapid adhesion, seal wounds continuously and effectively, and maintain long-lasting mechanical strength. The components of the tissue adhesive membrane come from natural components of animals and plants, have good biocompatibility, and possess the functions of antibacterial and inhibiting inflammation. The tissue adhesive membrane of the present invention is a hydrophobic adhesive membrane where hydrogen bonding and high surface energy can provide strong adhesion energy and no adverse active groups that may cause irritation or discomfort are contained.